SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-006237
Filing Date
2021-02-02
Accepted
2021-02-02 17:29:14
Documents
4
Period of Report
2021-02-02

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea134404-6k_nlspharmaceutics.htm 6-K 23333
2 AMENDED AND RESTATED ARTICLES OF ASSOCIATION ea134404ex3-1_nlspharma.htm EX-3.1 286814
3 NLS PHARMACEUTICS LTD. ANNOUNCES CLOSING OF $20.0 MILLION INITIAL PUBLIC OFFERIN ea134404ex99-1_nlspharma.htm EX-99.1 9959
4 GRAPHIC image_001.jpg GRAPHIC 10244
  Complete submission text file 0001213900-21-006237.txt   335315
Mailing Address ALTER POSTPLATZ 2 STANS V8 CH-6370
Business Address ALTER POSTPLATZ 2 STANS V8 CH-6370 41-41-618-80-00
NLS Pharmaceutics Ltd. (Filer) CIK: 0001783036 (see all company filings)

IRS No.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-39957 | Film No.: 21582857
SIC: 2834 Pharmaceutical Preparations